Kumar A, Chambers T C, Cloud-Heflin B A, Mehta K D
Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock 72205-7199, USA.
J Lipid Res. 1997 Nov;38(11):2240-8.
The signaling pathway involved in low density lipoprotein (LDL) receptor gene expression induced by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) was investigated in the human hepatoma HepG2 cell line. Treatment of HepG2 cells with 100 nM TPA resulted in an approximately 20-fold increase in LDL receptor mRNA level, as determined by RT-PCR, which peaked at 2-4 h of treatment and subsequently declined. The protein kinase C (PKC) inhibitors calphostin C and staurosporine prevented TPA-mediated LDL receptor mRNA induction. In contrast, TPA did not affect squalene synthase mRNA expression. Immunoblotting of cell extracts with isozyme-specific PKC antibodies revealed that HepG2 cells expressed PKC alpha, which was mainly cytosolic, and PKC beta, PK epsilon, and PKC zeta, all of which were present in both the cytosolic and particulate fractions. Treatment of HepG2 cells with 100 nM TPA resulted in translocation of cytosolic PKC alpha to the particulate fraction, with a maximum at 30 min-2 h of treatment, but was without effect on the subcellular distribution of the other isozymes. TPA treatment also led to activation of the mitogen-activated protein kinase (MAPK) ERK cascade. The specific MAPK pathway inhibitor PD98059 blocked TPA-induced ERK activation. Furthermore, pretreatment of cells with PD98059 inhibited TPA-induced LDL receptor mRNA induction. Moreover, pretreatment of cells with calphostin C inhibited TPA-mediated ERK activation and LDL receptor mRNA induction in a dose-dependent fashion. Based on a close kinetic correlation between PKC alpha translocation and ERK activation, and the effects of specific inhibitors, these findings suggest that translocation/activation of PKC alpha, and subsequent activation of the Raf-1/MEK/ERK MAPK cascade, represent key events in the transcriptional induction of LDL receptor gene by TPA in HepG2 cells.
在人肝癌HepG2细胞系中,研究了佛波酯12 - O -十四酰佛波醇-13 -乙酸酯(TPA)诱导低密度脂蛋白(LDL)受体基因表达所涉及的信号通路。用100 nM TPA处理HepG2细胞,通过逆转录聚合酶链反应(RT-PCR)测定,LDL受体mRNA水平增加了约20倍,在处理2 - 4小时达到峰值,随后下降。蛋白激酶C(PKC)抑制剂钙泊三醇C和星形孢菌素可阻止TPA介导的LDL受体mRNA诱导。相反,TPA不影响角鲨烯合酶mRNA表达。用同工酶特异性PKC抗体对细胞提取物进行免疫印迹分析表明,HepG2细胞表达PKCα,其主要存在于细胞质中,还表达PKCβ、PKCε和PKCζ,它们在细胞质和颗粒部分均有存在。用100 nM TPA处理HepG2细胞导致细胞质PKCα转位至颗粒部分,在处理30分钟至2小时达到最大值,但对其他同工酶的亚细胞分布没有影响。TPA处理还导致丝裂原活化蛋白激酶(MAPK)ERK级联反应的激活。特异性MAPK途径抑制剂PD98059可阻断TPA诱导的ERK激活。此外,用PD98059预处理细胞可抑制TPA诱导的LDL受体mRNA诱导。而且,用钙泊三醇C预处理细胞以剂量依赖方式抑制TPA介导的ERK激活和LDL受体mRNA诱导。基于PKCα转位与ERK激活之间密切的动力学相关性以及特异性抑制剂的作用,这些发现表明PKCα的转位/激活以及随后Raf-1/MEK/ERK MAPK级联反应的激活是TPA在HepG2细胞中诱导LDL受体基因转录的关键事件。